Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
Status: | Completed |
---|---|
Conditions: | Ocular |
Therapuetic Areas: | Ophthalmology |
Healthy: | No |
Age Range: | 55 - 90 |
Updated: | 1/1/2014 |
Start Date: | February 2012 |
End Date: | August 2013 |
Contact: | Novartis Pharmaceuticals |
Phone: | 1-888-669-6682 |
A Multicenter, Randomized, Sham-controlled, Repeat-dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG316 in Patients With Neovascular Age-related Macular Degeneration
This study will assess the safety and efficacy of LFG316 in patients with age related
macular degeneration.
macular degeneration.
Inclusion Criteria:
- Best corrected visual acuity (ETDRS scale) of 60 letters or less in the study eye.
- An active choroidal neovascular membrane attributable to neovascular AMD in at least
one eye.
- History of treatment (at any time) with at least 3 doses of anti-VEGF therapy in the
study eye.
Exclusion Criteria:
- History of recurrent non-response to anti-VEGF therapy in the study eye.
- In the study eye, retinal disease other than AMD (benign conditions of the vitreous
and peripheral retina are not exclusionary).
- Choroidal neovascularization due to a cause other than AMD.
- In the study eye, media opacity that, in the investigator's opinion, could interfere
with conduct of the study.
- History of infectious uveitis or endophthalmitis in either eye.
- Any of the following treatments to the study eye within 28 days prior to dosing:
ranibizumab, bevacizumab, pegaptanib or other VEGF inhibitor.
- Any of the following within 90 days prior to dosing: photodynamic therapy or laser
photocoagulation in the study eye; intravitreal steroid in the study eye; or
intraocular surgery (including cataract surgery) in the study eye
We found this trial at
11
sites
Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials
